TITLE

Potentials of on-line repositioning based on implanted fiducial markers and electronic portal imaging in prostate cancer radiotherapy

AUTHOR(S)
Graf, Reinhold; Wust, Peter; Budach, Volker; Boehmer, Dirk
PUB. DATE
January 2009
SOURCE
Radiation Oncology;2009, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: To evaluate the benefit of an on-line correction protocol based on implanted markers and weekly portal imaging in external beam radiotherapy of prostate cancer. To compare the use of bony anatomy versus implanted markers for calculation of setup-error plus/minus prostate movement. To estimate the error reduction (and the corresponding margin reduction) by reducing the total error to 3 mm once a week, three times per week or every treatment day. Methods: 23 patients had three to five, 2.5 mm Ø spherical gold markers transrectally inserted into the prostate before radiotherapy. Verification and correction of treatment position by analysis of orthogonal portal images was performed on a weekly basis. We registered with respect to the bony contours (setup error) and to the marker position (prostate motion) and determined the total error. The systematic and random errors are specified. Positioning correction was applied with a threshold of 5 mm displacement. Results: The systematic error (1 standard deviation [SD]) in left-right (LR), superior-inferior (SI) and anterior-posterior (AP) direction contributes for the setup 1.6 mm, 2.1 mm and 2.4 mm and for prostate motion 1.1 mm, 1.9 mm and 2.3 mm. The random error (1 SD) in LR, SI and AP direction amounts for the setup 2.3 mm, 2.7 mm and 2.7 mm and for motion 1.4 mm, 2.3 mm and 2.7 mm. The resulting total error suggests margins of 7.0 mm (LR), 9.5 mm (SI) and 9.5 mm (AP) between clinical target volume (CTV) and planning target volume (PTV). After correction once a week the margins were lowered to 6.7, 8.2 and 8.7 mm and furthermore down to 4.9, 5.1 and 4.8 mm after correcting every treatment day. Conclusion: Prostate movement relative to adjacent bony anatomy is significant and contributes substantially to the target position variability. Performing on-line setup correction using implanted radioopaque markers and megavoltage radiography results in reduced treatment margins depending on the online imaging protocol (once a week or more frequently).
ACCESSION #
42095027

 

Related Articles

  • Higher Radiation Doses, Fewer Treatments.  // USA Today Magazine;Oct2011, Vol. 140 Issue 2797, p14 

    The article focuses on the results of a multicenter clinical trial which showed the efficacy and safety of higher doses of stereotactic body radiation therapy (SBRT) that involves fewer treatments to patients with low- to intermediate-risk prostate cancer.

  • For Locally Advanced PCa, Add Radiation. Schieszer, John // Renal & Urology News;Sep2010, Vol. 9 Issue 9, p24 

    The article offers information on the randomized international trial which reveals that standard treatment for men with advanced prostate cancer should be androgen deprivation therapy (ADT) and external beam radiation.

  • PROSTATE CANCER.  // Current Medical Literature: Urology;2005, Vol. 11 Issue 4, p93 

    This article discusses research being done prostate cancer. The study by S. J. Freedland et al dealt with the risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. The study by M. Bolla et al focused on randomized controlled clinical trial on...

  • Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Chin, J. L.; Ng, C-K; Touma, N. J.; Pus, N. J.; Hardie, R.; Abdelhady, M.; Rodrigues, G.; Radwan, J.; Venkatesan, V.; Moussa, M.; Downey, D. B.; Bauman, G. // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 1, p40 

    The objective was to evaluate the relative efficacy of cryoablation (CRYO) versus external beam radiation (EBRT) for clinically locally advanced prostate cancer in a randomized clinical trial. Patients with histologically proven, clinically staged as T2C, T3A or T3B disease were randomized with...

  • Alpharadin Heats Up Competition For Prostate Cancer Therapies. Moran, Nuala // BioWorld Today;9/27/2011, Vol. 22 Issue 187, p1 

    The article reports that results from the Phase III study of Alpharadin from Algeta ASA showed the alpha-emitting radiotherapy met the primary endpoint of overall survival and secondary endpoints, including a reduction in the number of bone fractures. It states that Alpharadin exhibited the...

  • Stereotactic Radiotherapy for Localized Prostate Cancer: Early Clinical Trial Results. King, Christopher R. // AUANews;Dec2008, Vol. 13 Issue 12, p10 

    The article presents information on early clinical trial results of a study involving stereotactic radiotherapy for localized prostate cancer. It states that the clinical tests were done with the use of the Cyberknife, an image guided device designed for robotic radiosurgery. The method...

  • Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Kellokumpu-Lehtinen, P-L; Hjälm-Eriksson, M; Thellenberg-Karlsson, C; Åström, L; Franzen, L; Marttila, T; Seke, M; Taalikka, M; Ginman, C // Prostate Cancer & Prostatic Diseases;2012, Vol. 15 Issue 3, p303 

    Background:Radical radiotherapy (RT) combined with androgen deprivation therapy is currently the standard treatment for elderly patients with localized intermediate- or high-risk prostate cancer (PC). To increase the recurrence-free and overall survival, we conducted an adjuvant, randomized...

  • Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial. Pisansky, Thomas M.; Pugh, Stephanie L.; Greenberg, Richard E.; Pervez, Nadeem; Reed, Daniel R.; Rosenthal, Seth A.; Mowat, Rex B.; Raben, Adam; Buyyounouski, Mark K.; Kachnic, Lisa A.; Bruner, Deborah W. // JAMA: Journal of the American Medical Association;4/2/2014, Vol. 311 Issue 13, p1300 

    IMPORTANCE Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, but its role as a preventive agent is undefined. OBJECTIVES To determine primarily whether tadalafil preserved erectile function in men treated with radiotherapy for prostate cancer, and secondarily to...

  • Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. King, M T; Viney, R; Smith, D P; Hossain, I; Street, D; Savage, E; Fowler, S; Berry, M P; Stockler, M; Cozzi, P; Stricker, P; Ward, J; Armstrong, B K // British Journal of Cancer;2/14/2012, Vol. 106 Issue 4, p638 

    Background:Men diagnosed with localised prostate cancer (LPC) face difficult choices between treatment options that can cause persistent problems with sexual, urinary and bowel function. Controlled trial evidence about the survival benefits of the full range of treatment alternatives is limited,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics